Pedro Medrano has accepted the position of vice president of engineering and program management at Sebacia. He will lead commercialization readiness for the Sebacia Treatment, a potential new in-office acne treatment that combines hair removal lasers with Sebacia Gold Microparticles to destroy sebaceous glands.
Prior to joining Sebacia, Medrano spent 15 years at St. Jude Medical, where he led numerous global, cross-functional teams in the development of Class III implantable devices and systems. Medrano also held business development positions with Novartis’ eye care division (CIBA VISION and Alcon) and The Innovation Factory, where he performed due diligence on refractive laser surgery, intraocular and contact lenses, and drug delivery devices.
“Sebacia is entering an exciting time as we are concluding our U.S. pivotal trial and planning for U.S. and European commercial launches of Sebacia Treatment for moderate to severe acne,” said Anthony Lando, CEO of Sebacia. “Pedro’s deep experience in product development, particularly in the regulated medical device space, will be extremely valuable in bringing a new, innovative acne treatment to the dermatology market.”
